Taxotere use in prostate cancer

Newsletter Sign Up

Carmustine
Skelaxin
Betaxolol
Lenalidomide

Taxotere use in prostate cancer

From the 1AMD Associazione Medici Diabetologi ; scientific information website board infodiabetes. it ; Turin, Italy; the 2Diabetes Unit, Chivasso Civic Hospital, Turin, Italy; the 3Diabetes Service, Moncalieri, Turin, Italy; the 4Diabetes Unit, San Martino Hospital, Genoa, Italy; the 5Diabetes Unit, CTO Hospital, Turin, Italy; and the 6Diabetology and Metabolic Disorders Center, Madonna del Soccorso Hospital, San Benedetto del Tronto, Ascoli Piceno, Italy. Address correspondence and reprint requests to Marco Gallo, MD, Diabetes Unit, Chivasso Civic Hospital--ASL7, Corso Galileo Ferraris, 3, 10034 Chivasso, Turin, Italy. E-mail: diabetologia asl7.to.it. Received for publication 4 February 2004 and accepted in revised form 6 February 2004. by the American Diabetes Association.
Renin is an enzyme released by the kidney in response to low blood pressure and volume. It cleaves the liver protein angiotensinogen to produce angiotensin I, an inactive protein which is converted to its active form, angiotensin II, by angiotensin converting enzyme ACE ; . See Diagram. ; The renin-angiotensin system RAS ; , as this pathway is known, can be inhibited at each step; ACE inhibitors, the first available pharmacological anti-hypertensives which have also been used to treat heart failure and complications of diabetes ; , prevent the formation of angiotensin II. Angiotensin II receptor blockers ARBs ; prevent the angiotensin II protein from docking at its membrane bound receptor--a union that results in constriction of the blood vessels leading to a rise in blood pressure Renin inhibitors would logically, by acting upstream in the RAS, provide the most comprehensive defense against high blood pressure, by inhibiting the formation of both angiotensins I and II angiotensin II can be formed in the presence of ACE inhibitors via an alternative pathway, the chymase system ; . And since angiotensin is the only known substrate for renin, this specificity ought to mean renin inhibition would be devoid of unrelated side effects. But stumbling blocks such as poor bioavailability and the prohibitive cost of synthesizing renin inhibitors--not to mention the medical and commercial successes of ACE inhibitors and ARBs--have, until recently, impaired clinical results and curbed Big Pharma appetite for the class. Roche's remikiren and Abbott's zanikiren, for example, each dropped out of clinical development. Only 25-50% of hypertensive patients reach target blood pressure with currently available therapies. But whether or not the world really needs yet another anti-hypertension drug may depend on the secondary effects of renin inhibition. "An added value to any blood-pressure lowering agent is end organ protection, " comments Speedel CEO Alice Huxley, PhD. "Renin inhibition may offer a protective effect on the heart and the kidneys and possibly other organs" in patients whose high blood pressure, diabetes, or other disease is causing organ damage. The patients received either taxotere ® 100 mg m 2 , 1-hour intravenous infusion every 21 days ; or paclitaxel 175 mg m 2 , 3-hour intravenous infusion every 21 days ; – each drug given at the dosage and schedule as approved by the emea and food and drug administration.

Taxotere extravasation

Deferred taxes resulting from timing differences are not recorded where this would lead to the recording of a net deferred tax asset that is not certain to be recovered. This also applies to deferred taxes arising from the carry forward of tax losses. The following companies are included in the French group tax election: Synthelabo lead company ; Ela France Ela Medical Ela Recherche Europar Institut Synthelabo pour le Progres de la Connaissance ` Laboratoires Delagrange Laboratoires Delalande Laboratoires Irex Laboratoires Joullie Laboratoires Pharmaceutiques Dentoria F-94.
Distribution of CYP1A1 after induction by omeprazole. To test the functional significance of the perivenous expression of the AHR, in vivo CYP1A1 induction experiments were performed. For this purpose we used omeprazole, a widely used antiulcer drug, that has been shown to cause induction of human CYP1A1 and CYP1A2, evidently via a ligand-independent but AHR-associated mechanism. Administration of omeprazole 140 mg kg ; for 7 days caused significant induction of CYP1A1 protein fig. 6 ; . Although the degree of induction was modest compared with 3MC, comparison of periportal and perivenous samples demonstrated that most of the induction took place in the perivenous region fig. 7 ; , which suggested the involvement of AHR in this process.
The study also showed that 61% of patients treated with the combination responded to treatment, compared to 34% of patients who received taxotere alone and tazorac.

Taxotere vs taxol

60. Sengelov L, Kamby C, von der Maase H. Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol 2001; 39: 634642. Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 2002; 3 12 ; : 738747. ` 62. Calabro F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol 2002; 20 3 ; : 158166. ` 63. Calabro F, Sternberg CN. High-risk metastatic urothelial cancer: chances for cure? Curr Opin Urol 2002; 12 5 ; : 441448. 64. Bellmunt J, Albanell J, Gallego OS et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 1992; 70: 19741979. Waxman J, Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 1993; 19 suppl. C ; : 2125. 66. Sternberg CN. Gemcitabine in Bladder Cancer. Semin Oncol 2000; 27 1 ; : 3139. 67. von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 2003; 3: 1119. Misset JL. Brief communication: use of the multitargeted antifolate pemetrexed Alimta ; in genitourinary cancer. Semin Oncol 2002; 29 1 Suppl 3 ; : 3639. 69. Sternberg CN, Vogelzang NJ. Gemcitabine, Paclitaxel, Pemetrexed and Other Newer Agents in Urothelial and Kidney Cancers. Crit Rev Oncol Hematol 2003; 46 Suppl: S105115. 70. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23 21 ; : 46024608. 71. Roth BJ, Dreicer R, Einhorn LH. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12 11 ; : 22642270. 72. Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 1996; 156 5 ; : 16061608. 73. Murphy BA, Johnson DR, Smith J et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc Soc Clin Oncol 1996; 15: Abstr. 617. 74. Dreicer R, Manola J, Roth BJ et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2000; 18 5 ; : 10581061. 75. Burch PA, Richardson RL, Cha SS et al. Phase II Trial of Combination Paclitaxel and Cisplatin in Advanced Urothelial Carcinoma UC ; . J Urol 2000; 164: 15381542. McCaffrey JA, Hilton S, Mazumdar M. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997; 15 5 ; : 18531857. 77. de Wit R, Kruit WH, Stoter G et al. Docetaxel Taxotere ; : an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy pretreated patients. Br J Cancer 1998; 78 10 ; : 13425. 78. Sengelov L, Kamby C, Lund B, Engelholm SA. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 1998; 16 10 ; : 33923397. 79. Dimopoulos MA, Bakoyannis C, Georgoulias V et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative. Ann Oncol 1999; 10 11 ; : 13851388. 80. Garcia del Muro X, Marcuello E et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 2002; 86 3 ; : 326330. 81. Sternberg CN, de Mulder P, Schornagel JH et al. Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors EORTC protocol 30924 ; . Eur J Cancer 2006; 42 1 ; : 5054. 82. Stadler WM. Gemcitabine doublets in advanced urothelial cancer. Sem Oncol 2002; 29 1 Suppl 3 ; : 1519.

Gemzar taxotere sarcoma

Patients treated with taxotere showed a 50 percent higher overall response rate compared to patients treated with doxorubicin 45 percent for taxotere vs 30 percent for doxorubicin and telithromycin.

1. Ferrer MI: The sick sinus syndrome in atrial 1968 2. Eyster JAE, Evans JS: Sino-auricular heart block.

Hello everybody, bec had her 5th round of taxotere this past tuesday, her counts are starting to climb and temodar Some texts are taxotere online taxotere taxoterre finished earlier than others, which atxotere means that tazotere the taxotere first ones would spend weeks taxotrre or even taxoterre months waiting for taxitere the rest to be completed.

The other thing that i think we will be presenting and has therefore represented that taxotere is one of the strength as actually in europe what we have represented at previous meetings and we will now put into final publication as we lock the data is that we have now shown in a head-to-head trail against taxotere was using weekly abraxane versus three weekly taxotere, that we have a statistically significant prolongation and a significant in terms of numbers of months progression free, time to tumor progression i mean, head-to-head against taxotere was significantly low with toxicities and tenex. The IS Adjacency Group The IS Adjacency Group is current and contains information about adjacencies to routers maintained by the Integrated IS-IS protocol The IS Adjacency Table Each adjacency to an IS corresponds to one entry in this table. isisISAdjTable OBJECT-TYPE SYNTAX SEQUENCE OF IsisISAdjEntry MAX-ACCESS not-accessible STATUS current DESCRIPTION "The table of adjacencies to Intermediate Systems." : : isisISAdjEntry OBJECT-TYPE SYNTAX IsisISAdjEntry MAX-ACCESS not-accessible STATUS current DESCRIPTION "Each entry corresponds to one adjacency to an Intermediate System on this system." INDEX isisSysInstance. OVERDOSAGE There is no known antidote for TAXOTERE overdosage. In case of overdosage, the patient should be kept in a specialized unit where vital functions can be closely monitored. Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. Patients should receive therapeutic G-CSF as soon as possible after discovery of overdose. Other appropriate symptomatic measures should be taken, as needed. In two reports of overdose, one patient received 150 mg m2 and the other received 200 mg m2 as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident. In mice, lethality was observed following single IV doses that were 154 mg kg about 4.5 times the recommended human dose on a mg m2 basis neurotoxicity associated with paralysis, non-extension of hind limbs, and myelin degeneration was observed in mice at 48 mg kg about 1.5 times the recommended human dose on a mg m2 basis ; . In male and female rats, lethality was observed at a dose of 20 mg kg comparable to the recommended human dose on a mg m2 basis ; and was associated with abnormal mitosis and necrosis of multiple organs. DOSAGE AND ADMINISTRATION Breast Cancer: The recommended dose of TAXOTERE is 60-100 mg m2 administered intravenously over 1 hour every 3 weeks. Non-Small Cell Lung Cancer: For treatment after failure of prior platinumbased chemotherapy, TAXOTERE was evaluated as monotherapy, and the recommended dose is 75 mg m2 administered intravenously over 1 hour every 3 weeks. A dose of 100 mg m2 in patients previously treated with chemotherapy was associated with increased hematologic toxicity, infection, and treatment-related mortality in randomized, controlled trials see BOXED WARNING, WARNINGS and CLINICAL STUDIES sections ; . For chemotherapy-nave patients, TAXOTERE was evaluated in combination with cisplatin. The recommended dose of TAXOTERE is 75 mg m2 administered intravenously over 1 hour immediately followed by cisplatin 75 mg m2 over 30-60 minutes every 3 weeks. Premedication Regimen: All patients should be premedicated with oral corticosteroids such as dexamethasone 16 mg per day e.g., 8 mg BID ; for 3 days starting 1 day prior to TAXOTERE administration in order to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions see BOXED WARNING, WARNINGS, and PRECAUTIONS sections ; . Dosage Adjustments During Treatment Breast Cancer: Patients who are dosed initially at 100 mg m2 and who experience either febrile neutropenia, neutrophils 500 cells mm3 for more than 1 week, or severe or cumulative cutaneous reactions during TAXOTERE therapy should have the dosage adjusted from 100 mg m2 to 75 mg m2. If the patient continues to experience these reactions, the dosage should either be decreased from 75 mg m2 to 55 mg m2 or the treatment should be discontinued. Conversely, patients who are dosed initially at 60 mg m2 and who do not experience febrile neutropenia, neutrophils 500 cells mm3 for more than 1 week, severe or cumulative cutaneous reactions, or severe peripheral neuropathy during TAXOTERE therapy may tolerate higher doses. Patients who develop grade 3 peripheral neuropathy should have TAXOTERE treatment discontinued entirely. Non-Small Cell Lung Cancer: Monotherapy with TAXOTERE for NSCLC Treatment After Failure of Prior Platinum-Based Chemotherapy Patients who are dosed initially at 75 mg m2 and who experience either febrile neutropenia, neutrophils 500 cells mm3 for more than one week, severe or cumulative cutaneous reactions, or other grade 3 4 non-hematological toxicities during TAXOTERE treatment should have treatment withheld until resolution of the toxicity and then resumed at 55 mg m2. Patients who develop grade 3 peripheral neuropathy should have TAXOTERE treatment discontinued entirely. Combination Therapy with TAXOTERE for Chemotherapy-Naive NSCLC For patients who are dosed initially at TAXOTERE 75 mg m2 in combination with cisplatin, and whose nadir of platelet count during the previous course of therapy is 25, 000 cells mm3, in patients who experience febrile neutropenia, and in patients with serious non-hematologic toxicities, the TAXOTERE dosage in subsequent cycles should be reduced to 65 mg m2. In patients who require a further dose reduction, a dose of 50 mg m2 is recommended. For cisplatin dosage adjustments, see manufacturers' prescribing information. Special Populations: Hepatic Impairment: Patients with bilirubin ULN should generally not receive TAXOTERE. Also, patients with SGOT and or SGPT 1.5 x ULN concomitant with alkaline phosphatase 2.5 x ULN should generally not receive TAXOTERE. Children: The safety and effectiveness of docetaxel in pediatric patients below the age of 16 years have not been established. Elderly: See Precautions, Geriatric Use. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy in elderly patients. PREPARATION AND ADMINISTRATION PRECAUTIONS TAXOTERE is a cytotoxic anticancer drug and, as with other potentially toxic compounds, caution should be exercised when handling and preparing TAXOTERE solutions. The use of gloves is recommended. Please refer to Handling and Disposal section. If TAXOTERE concentrate, initial diluted solution, or final dilution for infusion should come into contact with the skin, immediately and thoroughly wash with soap and water. If TAXOTERE concentrate, initial diluted solution, or final dilution for infusion should come into contact with mucosa, immediately and thoroughly wash with water. TAXOTERE for Injection Concentrate requires two dilutions prior to administration. Please follow the preparation instructions provided below. Note: Both the TAXOTERE for Injection Concentrate and the diluent vials contain an overfill. A. Preparation of the Initial Diluted Solution 1. Remove the appropriate number of vials of TAXOTERE for Injection Concentrate and diluent 13% Ethanol in Water for Injection ; from the refrigerator. Allow the vials to stand at room temperature for approximately 5 minutes. 2. Aseptically withdraw the entire contents of the appropriate diluent vial into a syringe by partially inverting the vial, and transfer it to the appropriate vial of TAXOTERE for Injection Concentrate. If the procedure is followed as described, an initial diluted solution of 10mg docetaxel mL will result. 3. Mix the initial diluted solution by repeated inversions for at least 45 seconds to assure full mixture of the concentrate and diluent. Do not shake and teniposide.

Taxotere gemzar combination

Sep 6, 2007 the researchers studied 22 patients who underwent neoadjuvant therapy combining docetaxel and a luteinizing hormone-releasing hormone analogue, estramustine cancerpage , taxotere plus estremustine confirmed superior to taxotere alone. 13. Wellens HJJ, Brugada P, Stevenson WG: Programmed electrical stimulation: Its role in the management of ventricular arrhythmias in coronary heart disease. Prog Cardiovasc Dis 1986; 29: 165-180 Kay GN, Epstein AE, Plumb VJ: Incidence of reentry with an excitable gap in ventricular tachycardia: A prospective evaluation utilizing transient entrainment. JAm Coll Cardiol and tenofovir. Allard, D. W., and C. R. Barman. 1994. The learning cycle as an alternative method for college science teaching. Bioscience 44: 99-101. Anderson, L. W., D. R. Kratwohl, P. W. Airasian, K. A. Cruikshank, R. E. Mayer, P. R. Pintrich, J. Raths, and M. C. Wittcock 2001. A taxonomy for learning, teaching, and assessing: A revision of Bloom's Taxonomy of educational objectives. Longman Publishers, New York, USA. Gardiner, H. 1987. Developing the spectrum of human intelligence. Harvard Educational Review: 76-82. Kloss, R. J. 1994. A nudge is best: Helping students through the Perry scheme of intellectual development. College Teaching 42: 151-154. Kolb, D. A. 1984. Experiential learning: experience as the source of learning and development. Prentice Hall, Englewoods Cliffs, New Jersey. Perry Jr., W. G. 1984. Forms of intellectual and ethical development in the college years: A scheme. Holt, Rinehart, and Winston, New York, New York, USA. Svinicki, M. D., and N. M. Dixon. 1987. The Kolb model modified for classroom activities. College Teaching 35: 141-146. W.G. Perry, J. 1970. Forms of intellectual and ethical development in the college years: A scheme. Holt, Rinehart, and Winston, New York, New York and taxotere.
Markswise Tentative ; list of Candidates : General Category Page No 188 * The list prepared is likely to change on submission of proof of weightage as permissible under the PU rules. * Rank combined: PCB PCM PCT PCS S.No Roll No Candidate's Name Code Rank Marks Rank Category CET Combined 5424 404293 GEETIKA AHUJA PCB 3739 69.50 5410 GN 5425 407759 HARMANPREET KAUR PCB 3739 69.50 5410 GN D1 PCT[5016] 5426 408974 AMIT THAKUR PCM 810 69.50 5410 GN 5427 409016 CHARANJEET KAUR PCM 810 69.50 5410 GN 5428 409639 MOHIT SINGLA PCM 810 69.50 5410 TV 5429 409819 KIRTI AGGARWAL PCM 810 69.50 5410 GN 5430 409429 HARWINDER SINGH PCM 810 69.50 5410 GN D3 5431 410165 RAVINDER SINGH PCS 31 69.50 5410 GN PCM[4186] 5432 407321 NEHA LAKRA PCT 833 69.50 5410 ST PCB[6178] 5433 407102 NAVDEEP KAUR PCT 833 69.50 5410 GN D5 PCB[5948] 5434 407486 JASWINDER SINGH ANAN PCT 833 69.50 5410 GN PCB[3965] 5435 407331 NEHA JOSEPH PCT 833 69.50 5410 GN TV PCB[6111] 5436 407459 SUMEET KAUR DHANOA PCT 833 69.50 5410 GN PCB[5334] 5437 407504 NAVJOT KAUR PCT 833 69.50 5410 GN PCB[5948] 5438 407462 MUKTA SHARMA PCT 833 69.50 5410 GN PCB[5798] 5439 407851 GAGANDEEP BRAHIA PCT 833 69.50 5410 GN PCB[4889] 5440 405544 RITIKA KALIA PCB 3755 69.00 5440 GN 5441 403509 DEEPIKA BHARTI PCB 3755 69.00 5440 SC 5442 401049 NAVNEET KAUR CHEEMA PCB 3755 69.00 5440 GN SP 5443 405586 MANU KALIA PCB 3755 69.00 5440 GN 5444 404432 NAVDEEP KAUR PCB 3755 69.00 5440 GN 5445 408362 MEGHA MITTAL PCB 3755 69.00 5440 GN PCM[6249] 5446 408341 SUKHMEEN KAUR PCB 3755 69.00 5440 GN PCM[5869] 5447 407962 ANKUSH PREENJA PCB 3755 69.00 5440 GN PCT[5573] 5448 403737 REETIKA CHOPRA PCB 3755 69.00 5440 SP 5449 404490 TANUSHREE KAPOOR PCB 3755 69.00 5440 GN 5450 403763 SUMMERBIR KAUR SRAN PCB 3755 69.00 5440 GN 5451 404315 KIRTI JAIN PCB 3755 69.00 5440 GN 5452 406047 RAMANDEEP KAUR PCB 3755 69.00 5440 GN and tequin.

Chemotherapy taxotere cytoxan

2.5.4 Potentiation of the disinfectant effect with alkali and enzyme wash B. cereus present in pipes and heat exchangers represents a potential quality problem for the dairy industry. Disinfectants based on peroxygen can eliminate spores, but they are corrosive at high temperatures and concentrations Russell, 1990; Bloomfield, 1992; Bloomfield & Arthur, 1994; Russell & Chopra, 1996 ; . In the dairy industry, disinfection of pipes, tanks and pasteurizers is preceded by an alkali wash, often using temperatures above 60 C, and alkali-treated spores are usually not used when testing the sporicidal effects of disinfectants. Contact with alkali could make the spores sensitive to peroxygen, reducing the concentration needed to obtain an acceptable killing level. Resistance of spores to peroxygen Blakistone et al. 1999 ; determined the lethal effect of Oxonia Aktiv 2%, 40 C ; on a number of spore-forming bacteria and showed that B. cereus spores were the most resistant. The resistance of Bacillus spores to disinfection varies with the strain, sporulation, harvesting and washing procedure, and storage conditions and recovery conditions Waites & Bayliss, 1980 ; . B. cereus ATCC 9139 spores were used in this study, because preliminary experiments revealed this strain to be the most resistant to Oxonia Aktiv compared with 8 B. cereus strains isolated from the Norwegian dairy industry not shown ; . The higher resistance shown by of B. cereus ATCC strains than by dairy isolates to chlorine disinfectants was demonstrated by Te Giffel et al. 1995 ; . The sporicidal effect of disinfectants increases with temperature and exposure time Bloomfield, 1992 ; . A relatively high temperature 40 C ; and long exposure time 30 min ; were required to obtain a significant reduction in B. cereus viable counts when applying the highest recommended in-use concentration of Oxonia Aktiv. Exposure to the recommended in-use concentration of another peroxygen-containing disinfectant, Parades 0.25% ; , was also not sporicidal for intact spores. The results suggested that the disinfectant must be used at either high concentrations or at high temperatures to be able to eliminate spores Appendix 12 ; . Apparently this is not suitable for practical disinfection due to corrosion and toxicity.

Taxotere effectiveness

Prepatellar bursitis lump, molluscum contagiosum kids health, scrubs braff, heterokaryon cell and dexedrine effexor. My heroine lyrics, 1st trimester testing, cimetidine sol and emend egypt management or xifaxan information.

Taxotere red hands

Taxofere, taxotrre, taxot4re, taxotfre, taxtere, taxoterf, taxotdre, taxoterr, taxogere, tadotere, taxxotere, 5axotere, taxot3re, taxoteer, taxote5e, taxtoere, taxotwre, taaxotere, taxoter4, yaxotere.

Taxotere chemotherapy side effects

Taxotere and side effects, taxotere extravasation, taxotere vs taxol, gemzar taxotere sarcoma and taxotere gemzar combination. Chemotherapy taxotere cytoxan, taxotere effectiveness, taxotere red hands and taxotere chemotherapy side effects or taxotere nerve pain.